Introduction
This analysis examines the historical and forecast performance for Bristol-Myers Squibb in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
Highlights
Strategic insight into the prospects for BMS over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
This analysis examines the historical and forecast performance for Bristol-Myers Squibb in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Bristol-Myers Squibb's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for BMS over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark BMS's performance against key rivals in the prescription pharmaceutical sector
- Determine the value of BMS's piepline and other strategies the company is taking to counteract an imminent wave of generic compeitition.
- Assess what makes BMS a model biopharma company and why its newfound focus could lead to the industry's next megamerger.
Executive Summary
Key findings
Bristol-Myers Squibb prescription pharma sales outlook
Bristol-Myers Squibb financial outlook
Key developments
[Missing title]
Upcoming developments
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Strategic Insight
Company Introduction
Company Sales
Company Financials
Key Products
Data sourcing
Analyst consensus
STRATEGIC INSIGHT
Key findings
Strategic insight
BMS expiry decline fastest of Big Pharma
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
Squibb
Bristol-Myers Squibb
M&A strategy
M&A history
M&A strategy
SALES ANALYSIS
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2004–16
Product analysis
Product analysis, 2004–10
Product analysis, 2010–16
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Launch analysis, 2010–16
Core analysis, 2010–16
Expiry analysis, 2010–16
Launch/core/expiry configuration, 2010–16
Molecule type analysis
Externalization analysis
FINANCIAL ANALYSIS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2004-10
Operating costs and profit analysis
Operating performance analysis, 2004–10
Operating performance analysis, 2010–16
PRODUCT ANALYSIS
Overview
Plavix
Sprycel
Orencia
Reyataz
Baraclude
Onglyza
Nulojix
Sustiva
Dapagliflozin
Bristol-Myers Squibb pipeline overview
APPENDIX
Abbreviations
Exchange rates
Key findings
Bristol-Myers Squibb prescription pharma sales outlook
Bristol-Myers Squibb financial outlook
Key developments
[Missing title]
Upcoming developments
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Strategic Insight
Company Introduction
Company Sales
Company Financials
Key Products
Data sourcing
Analyst consensus
STRATEGIC INSIGHT
Key findings
Strategic insight
BMS expiry decline fastest of Big Pharma
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
Squibb
Bristol-Myers Squibb
M&A strategy
M&A history
M&A strategy
SALES ANALYSIS
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2004–16
Product analysis
Product analysis, 2004–10
Product analysis, 2010–16
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Launch analysis, 2010–16
Core analysis, 2010–16
Expiry analysis, 2010–16
Launch/core/expiry configuration, 2010–16
Molecule type analysis
Externalization analysis
FINANCIAL ANALYSIS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2004-10
Operating costs and profit analysis
Operating performance analysis, 2004–10
Operating performance analysis, 2010–16
PRODUCT ANALYSIS
Overview
Plavix
Sprycel
Orencia
Reyataz
Baraclude
Onglyza
Nulojix
Sustiva
Dapagliflozin
Bristol-Myers Squibb pipeline overview
APPENDIX
Abbreviations
Exchange rates